Amgen's Prognosis: Good, Not Assured
The biotech blue chip is seeing a payoff from its Immunex purchase. Is the new-drug pipeline big enough to keep profits healthy and growing?
By Amy Tsao
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.